Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 290

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 290
---
          —            —                5      —      
  Total                                                   46,469                       100.0      47,295       100.0       49,753      100.0  

Investments in equity investees mainly consisted of our investment in Shanghai Hutchison Pharmaceuticals. The fluctuation in the investments in equity investees was primarily due to recording our equity in earnings of Shanghai Hutchison Pharmaceuticals, net of tax, offset by dividends declared.

The following table shows our investment in our equity investee as of the dates indicated.

                                          As of December 31,              
                                          2024                      2023  
 ──────────────────────────────────────────────────────────────────────────
                                          $ ’ 000                         
  Shanghai Hutchison Pharmaceuticals      77,765                  48,411  

The following table shows the financial position of Shanghai Hutchison Pharmaceuticals as of the dates indicated.

                               As of December 31,                 
                                             2024           2023  
 ──────────────────────────────────────────────────────────────────
                                          $ ’ 000                 
  Current assets                          213,707        201,025  
  Non-current assets                       67,561         73,939  
  Current liabilities                   (126,154)      (179,649)  
  Non-current liabilities                 (3,859)        (3,687)  
  Net assets                              151,255         91,628  

Table of Contents

Results of Operations

The following table sets forth a summary of our consolidated results of operations for the years indicated, both in absolute amounts and as percentages of our revenue. This information should be read together with our consolidated financial statements and related notes included elsewhere in this annual report. Our operating results in any period are not necessarily indicative of the results that may be expected for any future period.

                                                          Year Ended December 31,                                                                    
                                                                             2024                       2023                       2022              
                                                                          $ ’ 000           %        $ ’ 000           %        $ ’ 000           %  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenue                                                                 630,201       100.0        837,999       100.0        426,409       100.0  
  Cost of revenue                                                       (348,884)      (55.4)      (384,447)      (45.9)      (311,103)      (73.1)